Evidence exists to suggest the plausibility of these serotherapeutic-based interventions for the management of IBD, for example, (1) a senolytic combination of D + Q (Dasatinib and Quercetin) has been demonstrated to reduce intestinal inflammation [104]; (2) anti-diabetic and senomorphic drug metformin has been recently reported to protect against IBD [105]; and (3) a monoclonal antibody toward IL-1β (canakinumab) has also shown effectiveness among older patients with IBD [106]. Here, IL1B is linked to inflammatory bowel disease.